文献速递乳腺癌

年轻BRCA1/2携带者HER2阴性早期乳腺癌化疗方案与生存

Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.
PubMed 文献 · Eur J Cancer · 2026-08-11

该国际多中心回顾性队列研究纳入4200例≤40岁、I-III期HER2阴性早期乳腺癌的BRCA携带者,比较蒽环-紫杉、蒽环无紫杉及非蒽环方案与生存的关系,中位随访8.1年。多因素校正后各方案间DFS和OS无显著差异,TNBC中铂类使用亦未改善结局。

要点

  • 蒽环无紫杉 vs 蒽环-紫杉:DFS aHR 0.88(95%CI 0.73-1.05),OS aHR 1.20(95%CI 0.87-1.67)。
  • 非蒽环 vs 蒽环-紫杉:DFS aHR 1.07(95%CI 0.82-1.38),OS aHR 1.16(95%CI 0.68-2.0)。
  • TNBC中铂类使用与结局改善无关。

核心结论

  • 在年轻BRCA携带者HER2阴性早期乳腺癌中,不同化疗方案间生存结局无统计学显著差异。

研究设计与样本

  • BRCA BCY协作组(NCT03673306)国际多中心回顾性队列研究。
  • 纳入2000-2020年诊断的≤40岁、I-III期乳腺癌BRCA携带者,共4200例接受(新)辅助化疗的HER2阴性患者,来自109个中心。
  • 中位随访8.1年(IQR 4.7-12.6年)。

主要发现

  • 58.7%为TNBC;蒽环-紫杉、蒽环无紫杉、非蒽环方案分别占74.4%、19.3%、6.3%。
  • TNBC病例中19.8%接受铂类治疗。
  • 多因素校正后,蒽环无紫杉 vs 蒽环-紫杉:DFS aHR 0.88(95%CI 0.73-1.05),OS aHR 1.20(95%CI 0.87-1.67)。
  • 非蒽环 vs 蒽环-紫杉:DFS aHR 1.07(95%CI 0.82-1.38),OS aHR 1.16(95%CI 0.68-2.0)。
  • TNBC中铂类使用未与结局改善相关。

临床怎么用

  • 对于年轻BRCA携带者HER2阴性早期乳腺癌,蒽环-紫杉、蒽环无紫杉或非蒽环方案均可考虑,生存无显著差异。
  • TNBC中铂类使用未显示生存获益,需个体化决策。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence to guide (neo)adjuvant chemotherapy choices in carriers of germline BRCA1/BRCA2 pathogenic variants (BRCA carriers) with early breast cancer (BC) is limited. We evaluated the association of different chemotherapy regimens with survival outcomes in this population. METHODS: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, retrospective cohort study of BRCA carriers diagnosed with stage I-III BC at age ≤ 40 years, between 2000 and 2020. Disease-free survival (DFS) and overall survival (OS) were assessed among patients with HER2-negative disease treated with anthracycline-taxane, anthracycline-no-taxane, or non-anthracycline (neo)adjuvant chemotherapy. The association of platinum use with outcomes was evaluated in triple-negative breast cancer (TNBC). RESULTS: Among 4200 young BRCA carriers from 109 centres who received (neo)adjuvant chemotherapy for HER2-negative BC, 58.7% had TNBC. Median follow-up was 8.1 years (IQR, 4.7-12.6 years). Anthracycline-taxane, anthracycline-no-taxane, and non-anthracycline regimens were used in 74.4%, 19.3%, and 6.3% of patients, respectively. Platinum agents were administered in 19.8% of TNBC cases. After multivariable adjustment, no significant differences in DFS or OS were observed between anthracycline-no-taxane and anthracycline-taxane regimens (DFS adjusted hazard ratio [aHR] 0.88, 95% CI 0.73-1.05; OS aHR 1.20, 95% CI 0.87-1.67) or non-anthracycline regimens (DFS aHR 1.07, 95% CI 0.82-1.38; OS aHR 1.16, 95% CI 0.68-2.0). In TNBC, platinum use was not associated with improved outcomes. CONCLUSIONS: In young BRCA carriers with HER2-negative early BC, no statistically significant differences in survival outcomes were detected across different chemotherapy regimens. Our findings may inform future prospective studies evaluating chemotherapy de-escalation strategies in this genetically defined population.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bernstein-Molho R, Sella T, Delucchi V, et al. Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. Eur J Cancer. 2026. PMID: 42580099. doi:10.1016/j.ejca.2026.116937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。